Form 4: Zomedica COO Anthony Blair Granted 750,000 Stock Options

Zomedica Corp.'s Chief Operating Officer, Anthony K. Blair, has been granted 750,000 options to purchase common stock at an exercise price of $0.05 per share, vesting over four years.

Summary

• Anthony K. Blair, the Chief Operating Officer (COO) of Zomedica Corp., was granted 750,000 options to purchase common stock.
• The options have an exercise price of $0.05 per share.
• The grant date for these options is June 12, 2025.
• Vesting for the options will occur in stages: one quarter (1/4) of the options will vest on the first anniversary of the grant date (June 12, 2026), and 1/48 will vest monthly thereafter.
• The options are scheduled to be fully vested by June 11, 2029.
• The expiration date for these options is June 11, 2035.
• Following this transaction, Mr. Blair beneficially owns 750,000 derivative securities (options).

Sentiment

Score: 6

Explanation: The grant of stock options to a key executive is a standard compensation practice that aligns management's long-term interests with shareholder value, indicating a commitment to retention and performance. This is generally viewed as a neutral to slightly positive development.

Positives

• The grant of stock options to the COO aligns management's long-term interests with those of shareholders, incentivizing performance and retention.
• The options have a long expiration date (June 11, 2035), providing a significant window for the COO to benefit from potential stock price appreciation.

Risks

• The value of the options is dependent on the future market price of Zomedica Corp.'s common stock; if the stock price does not exceed the exercise price, the options may expire worthless.
• The vesting schedule means the COO must remain with the company for a period to fully realize the benefit of the options.

Future Outlook

The grant of these stock options indicates a long-term incentive for the Chief Operating Officer, aligning his future financial interests with the company's performance and shareholder value creation through June 2029 for vesting and until June 2035 for exercise.

Industry Context

The granting of stock options to key executives like the Chief Operating Officer is a common practice in the biotechnology and medical device industries, serving as a standard component of executive compensation packages designed to attract, retain, and motivate talent by linking their financial success to the company's long-term share price performance.

Comparison to Industry Standards

• The practice of granting stock options with multi-year vesting schedules is a standard compensation mechanism across the technology and healthcare sectors, including companies comparable to Zomedica Corp. in the veterinary diagnostics and therapeutics space.
• The exercise price of $0.05, while low, is typical for options granted at or near the current market price at the time of grant, especially for companies with lower share prices.
• The vesting schedule (1/4 after one year, then monthly for the remainder) is a common structure designed to ensure executive retention and long-term commitment, similar to plans observed at companies like IDEXX Laboratories or Zoetis for their executive compensation.

Related Party Transactions

• The grant of 750,000 stock options to Anthony K. Blair, the Chief Operating Officer, constitutes a related party transaction as it involves an executive (insider) and the company as part of his compensation package.

Stakeholder Impact

• Shareholders: The grant aims to align the COO's financial incentives with the company's stock performance, potentially benefiting shareholders if the stock price increases.
• Employees: This transaction is specific to executive compensation and does not directly impact the broader employee base, though it reflects the company's approach to executive retention.
• Management: The COO receives a significant long-term incentive, tying a portion of his future compensation directly to the company's stock value.

Next Steps

• The options will begin to vest on June 12, 2026, with subsequent monthly vesting until fully vested on June 11, 2029.
• The COO may exercise vested options at any time before the expiration date of June 11, 2035, subject to company policy and insider trading regulations.

Key Dates

Keywords

Zomedica Corp., ZOMDF, Stock Options, Executive Compensation, Insider Transaction, Form 4, Beneficial Ownership, COO, Anthony K. Blair